Slides
Page 1
Non-Viral Genetic Medicine Non-Viral Genetic Medicine Virtual KOL Event: Detalimogene voraplasmid with Surfactant October 15, 2026
Page 2
2 Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws, including the Private Securities Litigation Reform Act of 1995, and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking statements"). Forward-looking statements may be identified by the use of the words such as “forecast”, “intend”, “develop”, “expect”, “anticipate”, “become”, “believe”, “continue”, “could”, “estimate”, “goal”, “intends”, “may”, “might”, “plan”, “possible”, “project”, “should”, “strategy”, “future”, “potential”, “opportunity”, “target”, “term”, “will”, “would”, “will be” or similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding detalimogene’s potential efficacy, durability, safety, tolerability and ease of use profile, our current views and market research on the non-muscle invasive bladder cancer market, the depth, breadth and quality of our market research, our conclusions, implications or take-aways from the results of our market research, estimates, projections or forecasts of payer coverage of therapies, projected revenues for detalimogene at pricing parity with new therapies, the size of the addressable BCG unresponsive population, our expectations regarding the frequency or manner in which healthcare providers may use detalimogene, potential growth of the potential patient population, sequencing of products the development of detalimogene, the potential benefits of detalimogene, plans regarding regulatory interactions and potential biologics license application (“BLA”) submission for detalimogene, plans regarding updates on the LEGEND study, including clinical data and engagement with the FDA, the development of detalimogene, projections of market opportunity and market share, and the anticipated market acceptance of detalimogene, if approved, the potential benefits of combining a surfactant bladder wash with detalimogene, including the potential for increased efficacy and durability, estimates and forecasts of financial and performance metrics, projections of market opportunity and market share, the anticipated market acceptance of detalimogene, expectations and timing related to regulatory submissions and commercial product launches and the prospects for regulatory approval of detalimogene. These forward-looking statements are based on various estimates and assumptions, whether or not identified in this presentation, and on the current expectations of the management of enGene Therapeutics Inc. ("enGene"), are not predictions of actual performance, and are subject to risks and uncertainties. Such statements are subject to numerous important factors, risks and uncertainties, many of which are beyond enGene's control, that may cause actual events or results to differ materially from enGene's current expectations.For example, there can be no guarantee that detalimogene will successfully complete necessary clinical development phases, including achieving positive results in the pivotal cohort of the LEGEND study, or that those results or any feedback from regulatory authorities will ultimately lead to a BLA submission for, and the approval of, detalimogene. Management's expectations and, therefore, any forward-looking statements in this presentation could also be affected by risks, uncertainties and assumptions relating to a number of other factors, which could cause the Company’s actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the inability of preliminary clinical data to predict the final results of the trial; changes in the results fromenGene’s clinical trials, including due to new data collected from the ongoing LEGEND study or future studies, subsequent analysis of existing data, and audit and verification procedures; the content and timing of decisions made by the FDA and other regulatory authorities; the Company’s ability to recruit and retain qualified scientific and management personnel, establish clinical trial sites and enroll patients in its clinical trials, execute on the Company’s clinical development plans, and secure regulatory approval on anticipated timelines; and other risks and uncertainties detailed in filings with Canadian securities regulators on SEDAR+ and with the U.S. Securities and Exchange Commission (“SEC”) on EDGAR, including those described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2025 (copies of which may be obtained at www.sedarplus.ca or www.sec.gov). You should carefully consider the risks and uncertainties described in the “Risk Factors” section of such Annual Report, as well as other documents if and when filed by enGene from time to time with the SEC and Canadian securities regulators. If any of these risks materialize or our assumptions prove incorrect, actual events and results could differ materially from those contained in the forward-looking statements. There may be additional risks that enGene does not presently know or that enGene currently believes are immaterial that could also cause actual events and results to differ. In addition, forward-looking statements reflect enGene’s expectations, plans, or forecasts of future events and views as of the date of this presentation. enGene anticipates that subsequent events and developments will cause enGene’s assessments to change. While enGene may elect to update these forward-looking statements at some point in the future, enGene specifically disclaims any obligation to do so, unless required by applicable law. These forward-looking statements should not be relied upon as representing enGene’s assessments as of any date subsequent to the date of this presentation. Accordingly, undue reliance should not be placed upon the forward-looking statements contained herein. Intellectual Property This Presentation contains trademarks, service marks, trade names, copyrights, and products of enGene and other companies, which are the property of their respective owners. The use or display of third parties’ trademarks, service marks, trade names, copyrights, or products in this Presentation is not intended to, and does not, imply a relationship with enGene, or an endorsement of or sponsorship by enGene. Solely for convenience, the trademarks, service marks, and trade names referred to in this Presentation may appear without the ®, TM or SM symbols, but such references are not intended to indicate, in any way, that enGene will not assert, to the fullest extent permitted under applicable law, its rights or the rights of the applicable licensor in such trademarks, service marks and trade names. Industry and Market Data This Presentation relies on and refers to certain information and statistics based on estimates by enGene’s management and/or obtained from third party sources which enGene believes to be reliable. enGene has not independently verified the accuracy or completeness of any such third party information, which involves elements of subjective judgment and analysis that may or may not prove to be accurate. None enGene, or its affiliates or any third parties that provide information to enGene or its affiliates, such as market research firms, guarantees the accuracy, completeness, timeliness, or availability of any information. Neither enGene nor its affiliates nor any third parties that provide information to enGene and its affiliates, such as market research firms, is responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or the results obtained from the use of such content. enGene may have supplemented such information where necessary, taking into account publicly available information about other industry participants and enGene management’s best view as to information that is not publicly available. Neither enGene nor its affiliates give any express or implied warranties with respect to the information included herein, including, but not limited to, any warranties regarding its accuracy or of merchantability or fitness for a particular purpose or use, and they expressly disclaim any responsibility or liability for direct, indirect, incidental, exemplary, compensatory, punitive, special, or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with the use of the information herein. Lead Program (detalimogene voraplasmid) The lead program described herein is an investigational drug therapy that has not been subject to testing designed to demonstrate that the therapy is effective in humans or to provide a basis to predict in advance whether an adequate level of efficacy in humans will be demonstrated in further testing. Although the FDA has indicated that the Phase 2 portion of the current LEGEND study may potentially support BLA approval, that outcome will depend entirely on the final results of Phase 2 clinical testing and other factors. Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 3
3 Discussion Outline 01 Agenda & Opening Remarks PRESENTER Ron Cooper Chief Executive Officer, enGene 02 Clinical Case Studies Community Urology Key Opinion Leaders PRESENTERS Susan Merrill, MD, FACS David Cahn, MD 03 Preclinical Deep Dive Detalimogene with Surfactant PRESENTER Anthony Cheung, PhD Co-Founder, enGene 04 Question & Answer Session PRESENTERS Ron Cooper Anthony Cheung Susan Merrill David Cahn Colorado Urology Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 4
4 Detalimogene: Investigational Next-Generation Therapy for NMIBC Expanding NMIBC Opportunity More treatment options may increase sequencing and expand the treatable population Market growth creates room for multiple therapies Scalable Non-Viral Platform Simplified storage / handling designed for broad community adoption Low-cost, readily available components support scalable manufacturing CDRP supports BLA readiness Compelling Clinical Profile* 54% CR at any time within the range observed for approved products Potential best-in-class tolerability with low rates of TRAEs leading to treatment interruption or discontinuation Surfactant Lifecyle Management Opportunity Potential to improve CR and durability with a surfactant bladder rinse Potential to reduce dwell time from 60 minutes to 30 minutes $266M cash position** Key 4Q 2026 Milestones: Pivotal cohort 12-month data • FDA pre-BLA meeting • BLA filing * Reflective of interim data presented as of April 21, 2026 ** Cash and cash equivalents and short-term marketable securities as of July 31, 2026 TRAEs = treatment-related adverse events; CR = complete response; NMIBC = non-muscle-invasive bladder cancer; BLA = biologics license application; PI = product information. Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 5
5 Key Takeaways: Eligible Patient Pool, Pricing, and Segmentation Virtual KOL Event: Detalimogene with Surfactant October 2026 Eligible Patients • Eligible patient pool exceeds the annual BCG- Unresponsive incidence (i.e., 2L) • Patients will sequence therapies creating a compounding effect on the eligible pool New Price Point • Recently launched therapies for High-Risk NMIBC BCG-Unresponsive exceed $500,000/yr • NCCN guideline 2A dictates payer coverage at new price point Urology Practice Segments • ~40% of patients are in practices that consider the balance between efficacy, safety, available resources and practice economics 2L 3L 4L 2L 3L 2L ~20,000 eligible patients $200K $700K Academic Medical Center Health System / Hospital Clinical Excellence Economics - Focused Workflow - Constrained Resource - Limited $500K
Page 6
David Cahn, MD Suzanne Merrill, MD, FACS Colorado Urology Bladder Cancer Regional Leader Colorado Urology Director of Clinical Research CLINICAL CASE STUDIES
Page 7
7 Colorado Urology Practice Overview Virtual KOL Event: Detalimogene with Surfactant October 2026 COLORADO UROLOGY Community scale + clinical sophistication Denver metropolitan area and surrounding communities 30+ UROLOGISTS 18 LOCATIONS ~130K PATIENTS SERVED PART OF A LARGER NATIONAL GROUP United Urology Group: 200+ physicians and 50+ advanced practice providers CLINICAL RESEARCH CAPABILITIES Dedicated clinical research access to novel bladder and kidney cancer trials. Community-based investigators support evaluation of therapies in real-world practice. REGIONAL EXPERTISE IN BLADDER CANCER Patients have access to the most cutting-edge bladder and kidney cancer treatments and opportunities to engage in clinical trials that deliver highly anticipated novel therapies.
Page 8
8 Patient Overview, Medical History, Current Symptoms, and Personal Circumstances • 82-year -old Walter is retired • After his wife passed 2 years earlier, he moved into an apartment down the street from his daughter and 3 grandchildren • 80 pack -year history of smoking • History of peripheral vascular disease, coronary artery disease, COPD, and atrial fibrillation • Urinary frequency, urgency and urge incontinence, managed with Myrbetriq • He is on Eliquis for cardiac symptom management Suzanne Merrill, MD, FACS Case Study 1: Virtual KOL Event: Detalimogene with Surfactant October 2026 WALTER’S JOURNEY
Page 9
9 2022 2023 2024 FEB–MAR 2022 | BCG INDUCTION - IVI ×6 Walter’s Journey Presentation, Treatment Considerations, Recurrence, Next Steps Virtual KOL Event: Detalimogene with Surfactant October 2026 JAN 2022 | INITIAL PRESENTATION - Gross hematuria; positive cytology CT normal - Cystoscopy: diffuse erythema - TURBT: multifocal CIS - Poor candidate for cystectomy APR 2022 - Cystoscopy / TURBT: persistent CIS MAY–JUN 2022 - BCG Reinduction ×6 JUL 2022–JUN 2023 | BCG MAINTENANCE - Maintenance therapy with neg. cystoscopies - Poor candidate for cystectomy JUL 2023 | RECURRENCE - 2.5 cm papillary lesion - TURBT pathology: TaHG + CIS AUG 2023–AUG 2024 | GEM / DOCE - Induction IVI ×6 - Monthly maintenance - Cystoscopies neg. between treatments SEP 2024 | RECURRENCE - 2.5 cm papillary lesion - TURBT pathology: TaHG + CIS - Severe urgency and incontinence NEXT STEP Ineligible for cystectomy Additional bladder-sparing option needed Appointment logistics complicated by caregiver and child-care needs. Appointment logistics complicated by caregiver and child-care needs.
Page 10
10Virtual KOL Event: Detalimogene with Surfactant October 2026 70-year -old newly diagnosed male Retired business executive who travels frequently and maintains active lifestyle • Advisory and board work • Visits grandchildren on both coasts • Plays golf and tennis weekly No significant medical co -morbidities Lives with his wife of 35 years David Cahn, MD Case Study 2: Patient Overview, Medical History, Current Symptoms, and Personal Circumstances ALBERT’S JOURNEY
Page 11
11 Albert’s Journey Presentation, Treatment Considerations, Recurrence, Next Steps Virtual KOL Event: Detalimogene with Surfactant October 2026 JAN 2024 | INITIAL PRESENTATION - Gross hematuria - Positive cytology; CT normal - Cystoscopy: Multifocal lesions - TURBT path: pTaHG June 2025 | RECURRENCE - Cystoscopy: multifocal papillary lesion - TURBT path: pTaHG JULY 2025 - NOV 2025 | GEM/DOCE - Induction IVI × 6 - 2x monthly maint. - Significant burning / inability to hold each drug >30 min NOV 2025 | RECURRENCE - Small papillary recurrence - TURBT pTaHG 1.5cm Cystectomy refused, Inlexzo not tolerated due to severe lower urinary tract symptoms. Additional bladder-sparing option needed. (BCG-exposed – relevant) July 2024 - Disease evaluation – neg - Lost to follow up for 1 yr JAN 2024 - May 2024 - BCG Induction - + 1 maint. SEP 2026 | RECURRENCE - Negative white light cystoscopy - BLUE Light TURBT – BCG Unresponsive CIS 2024 2025 2026 DEC 2025 – SEP 2026 - BCG Induction IVI x 6 - + 2 Maint. Cycles
Page 12
Rationale Behind Detalimogene with Surfactant
Page 13
13 Insights: Rationale, Evidence, and Next Steps for Surfactant Cohort Scientific Preclinical Clinical Efficacy and Administration Surfactant Selection Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 14
14 Scientific Rationale Supporting a Surfactant Bladder Rinse Scientific Preclinical Clinical Efficacy and Administration Surfactant Selection Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 15
15 Detalimogene: Designed for Bladder-Localized Immune Activation Synergistic Stimulation of Specific Innate and Adaptive Immune Responses 1. Gao J, et al, inventors; enGene, Inc., assignee. US patent WO 2013/138930 A1. September 26, 2013. 2. Joshi S, et al. Presented at: 2025 ASCO GU Cancers Symp osium; February 13-15, 2025; San Francisco, CA. Abstract TPS886. 3. Narayan VM, et al. Poster presented at: 2025 ASCO GU Cancers Symposium; February 13 -15, 2025; San Francisco, CA. Abstract 826. 4. Taylor J, et al. Presented at: 2025 ASCO GU Cancers Symposium; February 13-15, 2025; San Francisco, CA. Abstract 802. 5. Steinberg JD, et al. Presented at: 2023 SUO ; November 28-December 1, 2023; Washington, DC. Abstract 112 • Detalimogene delivers plasmid DNA encoding 3 genes that activate the RIG-I pathway and drive expression of IL-12 • RIG-I activation triggers innate immune signaling and recruitment of antitumor NK and T cells • Localized IL-12 expression drives Th1 polarization of tumor-infiltrating –cells, antitumor cytokine production, and immune memory formation VA1 (RIG - I agonist dsRNA) IL - 12 eRNA11a (RIG - I agonist dsRNA) Detalimogene Voraplasmid Detalimogene Plasmid nanoparticle Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 16
16 Beyond Dose Escalation: Breaking the Sigmoidal Dose-Response Treatment Day 1 3 8 10 15 43 64 0.1 1 10 100 1000 250ug/mL 800ug/mL 2,500ug/mL Urine IL-12 in Phase 1 LEGEND 1st dose 2nd dose Findings • Sigmoidal dose-response in humans: Urine IL- 12 jumps from dose 250 to 800 ug/mL, then plateaus at 2,500ug/mL dose • Pre-clinical animal models had similar dose response profile Conclusions • Increasing detalimogene dose alone will not increase therapeutic gene expression Detalimogene shows a sigmoidal dose–response, consistent with other NMIBC gene therapies 800ug/mL was selected as the RP2 dose and given at week 1, 2, 5, 6 every 3 months cycle; weeks 3 and 4 are skipped to minimize saturation of gene transcription mechanism Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 17
17 Surfactants Increase Transfection of Gene Therapies Preclinical Evaluation Before and After Surfactant Incorporation 1: Cretostimogene developed with a pre-wash surfactant, DDM, before administration of drug. 2: Ramesh et al. Molecular Therapy Vol. 10, No. 4, 2004. doi:10.1016/j.ymthe.2004.07.002, same serotype adenovirus as cretostimogene, different genetic payload; 3: Approved with a surfactant, Syn 3, mixed in with the viral vector. 4: Yamashita, et al. Cance r Gene Therapy (2002) 9, 687–691. doi:10.1038/sj.cgt.7700488, same serotype adenovirus as Adstiladrin, different genetic payload. Cretostimogene-like2 virus: <5% transfection Adstiladrin-like virus4: Negligible transfection Surfactant (DDM) + Cretostimogene-like virus: Surfactant (Syn3) + Adstiladrin-like virus: >90% transfection Transfection Most Urothelial Cells Bladders Harvested Bladder Cretostimogene 1 Adstiladrin 3 Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 18
18 Selection of Polidocanol for Surfactant Bladder Rinse Scientific Clinical Efficacy and Administration Preclinical Surfactant Selection Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 19
19 Selection Criteria: Commercial Availability and Extensive Safety Data ❑ Commercially Available: surfactant must already be commercially available to ensure immediate, uninterrupted supply ❑ Global Access: GMP-grade material must be manufactured at scale, at low cost of goods, and available in all regions where sites are located ❑ Safety: extensive safety data are required to ensure detalimogene's best- in-class tolerability is not compromised Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 20
20 Tested Multiple Agents Before Proceeding with Polidocanol Note: DDM = n-Dodecyl-β-D-maltoside, PLL = Poly-L-Lysine , N-9 = nonoxynol-9. Part 1 experiments used a reporter formulation identical to detalimogene but RIG-I and IL-12 sequences were replaced with luciferase No Rinse 0.1% DDM 70kDa 150kDa 0.25% N-9 0 2×105 4×105 6×105 Transgene Expression in Bladder Total Luciferase / Total Prot (mg) 5-min 0.01% PLL 15-min 5-min 0 100 200 300 400 500 pg mIL-12 / mg total protein 0.25% N-9 5-min 0.25% polidocanol 5-min mIL12 protein expression in Bladder no Rinse Part 1 Part 2 N-9 matched gene transfer of benchmark comparator (DDM) Polidocanol offered greater increase in gene transfer and had broader regulatory access N - 9 supply chain challenges Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 21
21 Polidocanol is Commercially Available with Extensive Safety Data Concentration for Bladder Rinse Clinical Development : 0.25% polidocanol Established Clinical and Safety Profile of Polidocanol: • Clinical Use: 1-4% IV sclerosing agent for varicose veins, telangiectasias and hemorrhoids • Consumer Use: Used in shampoos and other products at 1% • Safety: NOAEL 1 mg/kg/day (13-week IV rat study); ≤1% is non-irritating in rabbit eye ❑ Commercially Available: surfactant must already be commercially available to ensure immediate, uninterrupted supply ❑ Global Access: GMP-grade material must be manufactured at scale, at low cost of goods, and available in all regions where sites are located ❑ Safety: extensive safety data are required to ensure detalimogene's best-in-class tolerability is not compromised ✓ ✓ ✓ Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 22
22 Efficacy, Safety, and Administration for Detalimogene with Surfactant Scientific Clinical Preclinical Surfactant Selection Efficacy and Administration Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 23
23 Surfactant Enables Detalimogene to Reach Deeper Urothelial Cells Deeper urothelial penetration lets nanoparticles reach intermediate and basal cells, which have significantly higher transfectability • Cells near the basal lamina are more metabolically and endocytically active • This facilitates nuclear transport and transgene expression after vector entry • Higher metabolic activity may enable greater and longer-lasting gene expression, with potential to improve efficacy and durability Detalimogene Alone Detalimogene with Surfactant Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 24
24 Surfactant Rinse Increases Gene Expression 10X and Improves Efficacy Preclinical Murine Models Increases Gene Expression Improves Efficacy Sham N/A N/A SFT 0 10 20 30 40 50 Curing Rate % mEG-70 c800 mEG-70 c50 % Survived at Study End Murine*: A 5-min bladder rinse rescued the efficacy of a sub-optimal dose of deta 1 10 100 1000 0.1 1 10 100 1000 Detalimogene (Deta) μg/mL No pre-Tx 0.25% polidocanol (5 min) pg IL-12/mg protein 0 2 4 6 8 10 12 14 1 10 100 1000 Time course of mIL-12 expression Days post-tx pg mIL-12 / mg protein Murine: Surfactant leads to >10× increase in IL-12 expression for longer duration pg IL-12/mg protein *Orthotopic mouse model was used. Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 25
25 Surfactant Rinse May Reduce Patient Burden by Reducing Dwell Time Surfactant Bladder Rinse Improves Gene Expression at Shorter Dwell Times Shortens Bladder Dwell Time 0 250 500 750 1000 60 5 15 30 60Deta: (min) Ø 5 min SFT Pre-tx No Pre-tx pg IL-12/mg tissue protein A 5-min bladder rinse reduced the detalimogene dwell time from 60 to 15 min. Patients: preferred in patients with irritated or overactive bladders Practices: Frees up chair time, and increases patient throughput Virtual KOL Event: Detalimogene with Surfactant October 2026 Shorter Dwell Time
Page 26
26 Proven Anticancer Effect: Same Targets Upregulated by BCG • IL-12, IFN-γ and CXCL-10 drive anti-tumor immunity in the bladder, and are all upregulated by BCG • BCG's clinical benefit is direct evidence that these targets drive anti-cancer activity VA1 (RIG - I agonist dsRNA) IL - 12 eRNA11a (RIG - I agonist dsRNA) Established Effector Molecules IL-12 RIG-I Agonists IFN- CXCL-10 Effector molecules Virtual KOL Event: Detalimogene with Surfactant October 2026 Source: Ashiru O, et al. Cancers (Basel). 2019 Jul 4;11(7):940. doi: 10.3390/cancers11070940; Dix P Poppas et al. Urology 1998 Vol 52 (2) 268 -276. doi.org/10.1016/S0090-4295(98)00188-5; Riemensberger J, et al. Clin Exp Immunol. 2002 Jan;127(1):20-6. doi: 10.1046/j.1365-2249.2002.01734.x
Page 27
27 Surfactant: Enhances IL-12 Expression & Downstream Target Engagement * p<0.05; ** p<0.01; *** p<0.001 /w bladder rinse and 15min deta dwell No bladder rinse and 60min deta dwell 1 10 100 1000 Time course of mIL-12 expression pg mIL-12 / mg protein 48h 96h 7d 14d ✱✱✱ ✱✱ ✱✱ ✱✱ Naive Sustained Enhancement of IFN-γ Production Sustained Enhancement of CXCL- 10 Production Increased and Prolonged IL-12 Expression in Bladder 0 10 20 30 40 pg IFN-γ / mg protein ✱ ✱✱ ✱✱ ✱✱ 48h 96h 7d 14dNaive 0 100 200 300 pg CXCL10 / mg protein ✱ ✱ ✱ ✱ 48h 96h 7d 14dNaive Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 28
28 Maintain Detalimogene Simplicity by Not Requiring Multiple Rinses No Bladder Washout with Saline is Needed Before Detalimogene Administration 0.0 0.1 0.2 0.3 PDI max 75 100 125 150 175 Size (nm) max min -2 0 2 4 6 8 Zeta (mV) max min 5 6 7 8 pH max min 1 10 100 1000 pg mIL-12 / mg total protein ns 0.25% polidocanol Detalimogene Detalimogene + 0.025% polidocanol 0.25% polidocanolbladder rinse: Tx: P o ssible residual vo lume o f bladder rinse ( up to 10% ) in bladder/c at h et er has no impac t o n detalimo g e ne ( right hand graph) No Impact to Detalimogene Stability No Impact to Detalimogene Potency If surfactants disrupt the stability or potency of a drug then an extra wash step is required where saline is used to wash out the bladder, which can be disruptive to urologist workflow Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 29
29 Surfactant: No Observed Bladder Toxicity or Systemic Exposure Preclinical Evaluation in Murine 0 2 4 6 8 10 12 14 2 4 6 8 mIL-12 Protein Concentration in Plasma Days Post-Tx mIL-12 (pg/mL) 0 2 4 6 8 10 12 14 125 130 135 140 145 150 mIL-12 pDNA Concentration in Plasma Days Post-Tx copies / mL of plasma Bladder weight is a sensitive marker to track bladder toxicity Bladder weight unchanged with polidocanol Virtual KOL Event: Detalimogene with Surfactant October 2026 Naive 0 10 20 30 40 Bladder weight 48h Post-Tx bladder weight (mg) - Detalimogene 60 min 0.25% polidocanol 5-min + Detalimogene 15 min Bladder weight at 48h post-Tx pDNA in Plasma mIL-12 in Plasma Bladder Weight at 48h Post-Tx No pre- treatment
Page 30
30 Detalimogene Only Surfactant + Detalimogene No Pretreatment Detalimogene 60m 5-min Pretreatment Detalimogene 15m Increase Mean hIL-12 expression (pg/mg of total protein) 0.294 2.725 9X Magnitude % of positive samples 29% (7/24) 81% (29/36) +52% Distribution Increases Gene Expression Non-Human Primates Model Validates Gene Expression and Safety Findings 0h 2h 24h 48h 0 2 4 6 8 10 Polidocanol in Plasma Time post-administration ug/mL BLQ BLQ BLQ BLQ LLOQ BLQ: Below level of quantitation LLOQ: Lowest level of quantitation No systemic distribution of polidocanol following administration* *The bladder of NHPs (n=3) was rinsed with 0.25% polidocanol for 5-min and retrieved. The rinse was followed by an administration of detalimogene for 15-min. Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 31
31 Next Steps Studying Surfactant Bladder Rinse in a Clinical Trial Scientific Preclinical Clinical Efficacy and Administration Surfactant Selection Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 32
32 LEGEND Detalimogene + Polidocanol Surfactant Cohort First Patients Enrolled and Past Safety Run-In • Single-catheterization 5 min bladder rinse with 50 mL of 0.25% polidocanol prior to detalimogene administration • Intravesical dwell time for detalimogene reduced from 60 to 30 minutes • ~50 active enrolling sites across North America, Europe, and APAC Virtual KOL Event: Detalimogene with Surfactant October 2026 High-Risk NMIBC Study Design BCG-unresponsive HR NMIBC with CIS +/- Papillary Safety Run-In No Dose Limiting Toxicities Complete Efficacy Run-In In Progress Up to n=80 enrollment Note: patients are illustrative and not reflective of exact patient numbers for the safety and efficacy run-in of the trial.
Page 33
33 Detalimogene: Next Gen NMIBC Treatment Designed for Community Use Large Total Addressable Market Differentiated Total Product Profile Lifecycle Management Near-Term Planned Catalysts $266M Cash* Expect to Provide Operating Flexibility through Potential BLA Filing and Approval NMIBC market forecasted to be >$20B Surfactant Bladder Rinse has Potential to Improve Efficacy, Duration and Reduce Patient Burden Pivotal 12-month Data, Pre-BLA Meeting & BLA Initiation: Q4 2026 Potential Approval Decision & Platform Designation: 2027 Surfactant Cohort 6-month Data: Mid-2027 Demonstrated Clinical Activity, Favorable Safety, and a Streamlined Patient and Practice Experience Sources: Transparency market research NMIBC Market Outlook 2034. * Cash and cash equivalents and short-term marketable securities as of July 31, 2026. Virtual KOL Event: Detalimogene with Surfactant October 2026
Page 34
Q&A
Page 35
Thank You